UQ1 Stock Overview
Develops treatments for patients suffering from rare and other devastating diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
uniQure N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.38 |
| 52 Week High | US$9.64 |
| 52 Week Low | US$3.30 |
| Beta | 0.90 |
| 11 Month Change | -7.05% |
| 3 Month Change | 1.82% |
| 1 Year Change | -11.63% |
| 33 Year Change | -78.78% |
| 5 Year Change | -89.21% |
| Change since IPO | -57.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| UQ1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.1% | -0.7% | 0.2% |
| 1Y | -11.6% | -17.2% | 8.5% |
Return vs Industry: UQ1 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: UQ1 underperformed the German Market which returned 8.5% over the past year.
Price Volatility
| UQ1 volatility | |
|---|---|
| UQ1 Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: UQ1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: UQ1's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 480 | Matt Kapusta | www.uniqure.com |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.
uniQure N.V. Fundamentals Summary
| UQ1 fundamental statistics | |
|---|---|
| Market cap | €270.55m |
| Earnings (TTM) | -€229.99m |
| Revenue (TTM) | €27.45m |
9.9x
P/S Ratio-1.2x
P/E RatioIs UQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UQ1 income statement (TTM) | |
|---|---|
| Revenue | US$28.59m |
| Cost of Revenue | US$182.66m |
| Gross Profit | -US$154.08m |
| Other Expenses | US$85.43m |
| Earnings | -US$239.50m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.91 |
| Gross Margin | -538.97% |
| Net Profit Margin | -837.80% |
| Debt/Equity Ratio | 856.0% |
How did UQ1 perform over the long term?
See historical performance and comparison